Gilead Sciences Stock - FDA accepts filing for weekly HIV prevention pill

Gilead Sciences has reached a new regulatory milestone in HIV prevention. The FDA has accepted the company’s supplemental new drug application for once-weekly oral PrEP tablets based on lenacapavir, adding a fresh medium-term driver to the stock story.

Edited by ad hoc news Chart & Technicals Desk. Verified prior to publication on 06/18/2026, 15:10 UTC. Details in the imprint.

Gilead Sciences (US3755581036) has cleared a new regulatory hurdle in HIV prevention. The U.S. Food and Drug Administration has accepted its supplemental new drug application for once-weekly oral PrEP tablets based on lenacapavir, according to a recent analyst summary of company announcements.

FDA filing adds HIV catalyst

According to a Zacks analyst blog citing Gilead, the FDA has accepted a supplemental new drug application for Yeztugo (lenacapavir) 300 mg tablets as a potential once-weekly oral PrEP option for HIV prevention. The filing targets people at risk of HIV infection.

Lenacapavir is already approved in the United States as a twice-yearly subcutaneous injection for heavily treatment-experienced patients with multidrug-resistant HIV, marketed as Sunlenca. Extending the compound into prevention in oral form would broaden the commercial reach of Gilead’s HIV franchise over time.

Chart picture around key levels

Gilead Sciences shares most recently traded at about $125.45 on the Nasdaq, based on the last recorded quote from a real-time feed updated on 06/18/2026. Over recent sessions the stock has hovered close to this level after a strong rebound earlier in the year.

The shares remain sensitive to news around the company’s pipeline and to the broader healthcare sector mood. On balance, the new PrEP filing adds a clear narrative element on the growth side, while chart-wise the stock continues to work within its established trading range.

The product behind the stock

Gilead Sciences generates most of its revenue from antiviral therapies, with HIV medicines at the core of the business. Key brands include Biktarvy, a once-daily single-tablet regimen for HIV treatment, as well as Descovy for PrEP, Veklury for COVID-19 and various hepatitis C therapies.

Where the stock trades today

The shares of Gilead Sciences (US3755581036) trade on the Nasdaq at $125.45 as of 06/18/2026, 05:31 EDT.

Key facts on Gilead Sciences stock

• Company: Gilead Sciences, Inc.
• ISIN: US3755581036
• WKN: 885823
• Ticker: GILD
• Venue: Nasdaq
• Price (as of 06/18/2026, 05:31 EDT): 125.45 USD
• Market cap: 156,000,000,000 USD (as of 06/18/2026)
• Sector / Industry: Health Care - Biotechnology
• Index membership: S&P 500
• Next earnings date: not officially scheduled

This article was AI-assisted and editorially reviewed. Price and company data without warranty; prices and dates may change at short notice. No investment advice, no buy or sell recommendation. Trading securities involves risk up to total loss of capital.